Evidence for L‐dopa incorporation into cell proteins in patients treated with levodopa

Kenneth Rodgers, Peter Hume, John Morris, Roger Dean

    Research output: Contribution to journalArticlepeer-review

    31 Citations (Scopus)


    Levodopa (L-dopa) is the most widely used agent for the symptomatic relief of Parkinson's disease. There is concern that chronic L-dopa treatment may be detrimental, with some studies suggesting that L-dopa may be neurotoxic. A potentially important mechanism whereby L-dopa may exert neurotoxic effects has been overlooked: that of the incorporation of L-dopa into proteins by protein synthesis. L-Dopa competes with tyrosine as a substrate in protein synthesis in vitro. We provide evidence that L-dopa can also be incorporated into proteins in vivo. Blood from L-dopa-treated and -non-treated patients was separated into protein, erythrocyte and lymphocyte fractions and levels of protein-incorporated dopa quantified by HPLC. Levels of protein-incorporated dopa were significantly increased in lymphocyte cell proteins from L-dopa-treated patients. This has not arisen from oxidative pathways as there was no evidence of oxidative damage to proteins. In addition, there was no increase in protein-incorporated dopa in erythrocytes, which are not actively synthesizing proteins. We suggest that protein-incorporated dopa could also be generated in the CNS. The accumulation of protein-incorporated dopa in cells is associated with oxidative stress and impaired function and could contribute to some of the problems associated with long-term L-dopa treatment.
    Original languageEnglish
    Pages (from-to)1061-1067
    Number of pages7
    JournalJournal of Neurochemistry
    Issue number4
    Publication statusPublished - 2006


    Dive into the research topics of 'Evidence for L‐dopa incorporation into cell proteins in patients treated with levodopa'. Together they form a unique fingerprint.

    Cite this